论文部分内容阅读
目的通过检测淋巴瘤中Oct2蛋白的表达,观察其特异性和敏感性,探讨Oct2在淋巴瘤诊断和分类中的意义。方法应用免疫组织化学EnVision法检测并观察129例不同类型淋巴瘤和10例淋巴结反应性增生(RLH)中的Oct2蛋白表达。结果RLH中Oct2主要表达在生发中心细胞,而B细胞淋巴瘤则为弥漫阳性表达。Oct2阳性率在B细胞淋巴瘤为97.7%(85/87),与CD20阳性率90.8%(79/87)相比差异无统计学意义(P>0.05);与CD79α阳性率84.7%(61/72)相比差异有统计学意义(P<0.05)。Oct2阳性率在T细胞淋巴瘤为3.8%(1/26);在结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)和经典型霍奇金淋巴瘤(CHL)分别为3例均阳性和46.2%(6/13),后两组间比较P>0.05。结论作为B细胞淋巴瘤一种新的相对特异而敏感的标记物,Oct2抗体可能有助于淋巴瘤的诊断和分类,可作为诊断B细胞淋巴瘤的首选标记物之一。
Objective To detect the expression of Oct2 protein in lymphoma and to observe the specificity and sensitivity of Oct2 in the diagnosis and classification of lymphoma. Methods The expression of Oct2 protein in 129 cases of different types of lymphoma and 10 cases of lymph node reactive hyperplasia (RLH) was detected by EnVision immunohistochemistry. Results In RLH, Oct2 was mainly expressed in germinal center cells, while B-cell lymphoma was diffusely positive. The positive rate of Oct2 in B-cell lymphoma was 97.7% (85/87), which was not significantly different from that of CD20 (90.8%, 79/87) (P> 0.05) 72) compared with the difference was statistically significant (P <0.05). The positive rate of Oct2 was 3.8% (1/26) in T-cell lymphoma and 3 cases in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and classic Hodgkin lymphoma (CHL) Positive and 46.2% (6/13), P> 0.05 after the two groups. Conclusion As a new relatively specific and sensitive marker of B cell lymphoma, Oct2 antibody may contribute to the diagnosis and classification of lymphoma and may be one of the preferred markers for diagnosis of B cell lymphoma.